Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study.
Sign Up to like & getrecommendations! Published in 2021 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2021.102981
Abstract: BACKGROUND Anti-CD20 monoclonal antibodies (mAb) have demonstrated their drastic efficacy in the treatment of active relapsing-remitting multiple sclerosis (RR-MS). This study investigates the management of their initiation after another disease modifying therapy (DMT). The objective… read more here.
Keywords: monoclonal antibodies; switching towards; cd20 monoclonal; study ... See more keywords